ABT-510
Names | |
---|---|
IUPAC name
(2S)-1-[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2R,3S)-2-[[(2S)-2-[[2-[[2-[acetyl(methyl)amino]acetyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]pentanoyl]amino]-3-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-N-ethylpyrrolidine-2-carboxamide
| |
Identifiers | |
3D model (
JSmol ) |
|
ChEMBL | |
ChemSpider | |
DrugBank | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C46H83N13O11 | |
Molar mass | 994.250 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a "subcutaneously (SC) administered nonapeptide thrombospondin analogue."[1][2]
Following inconclusive
VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.[3]
References
- ^ "2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition)". J. Clin. Oncol. 22 (14S Suppl). July 15, 2004. 3080.
- ^ NCI: ABT-510 Archived September 28, 2007, at the Wayback Machine
- S2CID 24673041.